Browsing by Author "Ercan, Cihangir Mutlu"

Now showing 1 - 3 of 3

Comparison of risk of malignancy indices; RMI 1-4 in borderline ovarian tumor
(Imr Press, 2012) Yenen, Müfit Cemal; Aktürk, Erhan; Ozan, Hakan; Dede, Murat; Alanbay, İbrahim; Ercan, Cihangir Mutlu; Çoksuer, Hakan; Karaşahin, Kazım Emre; Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.; 0000-0003-3457-4283; 0000-0002-5511-6938; W-6909-2019; A-3349-2017; 23670183700; 8941445200; 6503917949; 28367755400
Purpose: The aim of this study was to evaluate prognostic values of the risk of malignancy index (RMI)/1-4 in patients with borderline ovarian tumors (BOTs). Methods: The study consisted of 50 patients with BOT diagnosed and treated between 2005-2010 and 50 patients with benign adnexal massses between 2009-2010 as a control comparison group in the retropsective study. Preoperative serum CA125, U score, tumor size (S), and menopausal status were recorded. The RMI 1-3 was calculated according to the formula; UxMxCA125 and RMI 4 formulation was; UxMxCA125xS. S equaled 1 for tumor size < 7 cm and was 2 when size >= 7 cm. The RMI 1-4 indices were calculated for all patients together with the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy (DA). The performances of RMI indices were evaluated by McNemar's test and determined the best score cutoff value by the receiver operating characteristic (ROC) curve. Results: The mean age, median value of CA 125, ultrasound score, menopausal status, median values of RMI 1-4 of BOTs were statistically higher than benign adnexal masses. The sensitivity of RMI 1-4 was 26, 36, 62, and 60% at cutoff 200 level, respectively. The areas under curve of RMI 1-4 were found to be 0.676, 0.665, 0.668 and 0.734, respectively. DA of RMI 1-4 was found to be 56, 59, 50, and 71, respectively. When RMI 1-4 indices were compared with each other RMI 4 was the best RMI for BOTs. Conclusion: RMI 4 was the best predictive RMI for preoperative discrimination of BOT at a cutoff level of 200.
Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors
(Imr Press, 2012) Alanbay, İbrahim; Aktürk, Erhan; Çoksüer, Hakan; Ercan, Cihangir Mutlu; Karaşahin, Kazım Emre; Dede, Murat; Yenen, Müfit Cemal; Dilek, Saffet; Ozan, Hakan; Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.; 7003908072
Objective: The aim of this study was to assess tumor markers and clinicopathological findings of patients with serous and mucinous borderline ovarian tumor (BOT) features. Methods: The study consisted of 50 patients that were diagnosed with and treated for BOT between 2005- 2010 in three centers. CA125, CA19-9, and CA125+CA19-9 levels and clinicopathological features were compared in serous and mucinous histotypes. In serous and mucinous BOTs, correlations between tumor markers and demographics such as age, menopausal status, parity, clinical findings (stage, relapse, adjuvant chemotherapy, cytology, lymph node involvement and tumoral morphology (cystic-solid content, papilla, septation) were evaluated. Results: There were no significant differences between serous and mucinous tumors in the clinicopathological features such as stage, tumor markers, age, menopausal status, or cytology. In serous BOTs we found a significant relation between elevated CA 125+ CA 19-9, CA 19-9 and recurrence (p<0.05). Also there was a significant relation between elevated CA 125+ CA 19-9, CA 19-9 and cytology positivity (p<0.05). We found a significant relation in serous BOTs between elevated CA125+CA19-9, adjuvant chemotherapy and lymph node metastases (p<0.05). Also In mucinous BOTs with papilla formation we found a significant relation between elevated CA125 and CA 125+ CA19-9 (p<0.05). There was significant relation between cytology positivity and elevated CA 19-9 in mucinous BOTs (p<0.05). Conclusion: Serum tumor markers of serous and mucinous BOTs were different in relation to their clinicopathological features. This may reflect differences of serous and mucinous BOTs.
Opu işlemi ve komplikasyonları
(Uludağ Üniversitesi, 2012-10-02) Sakıncı, Mehmet; Ercan, Cihangir Mutlu; Çetinkaya, Mehmet Bilge
In-vitro fertilizasyon (IVF) tedavisi ana hatları ile eksojen gonadotropinler kullanılarak yapılan kontrollü ovaryan hiperstimulasyon, ardından transvajinal ultrason eşliğinde overlerden oositlerin toplanması (OPU), embryoloji laboratuarında gerçekleştirilen fertilizasyon ve embryoların uterusa transservikal olarak transferi aşamalarından oluşmaktadır. OPU işlemi bu sürecin kısa bir dilimini oluştursa da, işlem sonrasında yeterli sayıda oosit elde edilebilmesi direkt olarak tedavi başarısı ile ilişkilidir. İşlemin uygun teknikle yapılması toplanan oosit sayılarının arttırılması ve hayatı tehdit edebilecek komplikasyonların önlenmesinde büyük öneme sahiptir. Biz bu derlememizde uygulayıcılar tarafından OPU tekniğinin optimize edilebilmesi için güncel literatürü gözden geçirerek en doğru tekniğin belirlenmesini hedefledik.